{"product_id":"igf-1-lr3","title":"IGF-1 LR3","description":"\u003cdiv class=\"framer-6nrd7l\" data-framer-name=\"Overview\"\u003e\n\u003cdiv class=\"framer-e299os\" data-framer-name=\"Overview Header\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cdiv class=\"framer-17icvk9\" data-framer-name=\"Strong → Research Use Only.\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cp class=\"framer-text framer-styles-preset-dbnhlu\" data-styles-preset=\"UNBSR8FY_\" dir=\"auto\"\u003e\u003cem\u003e\u003cstrong\u003eResearch Use Only\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-1j4pnbk\" data-framer-name=\"Strong → Research Use Only.\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cp class=\"framer-text framer-styles-preset-1ejfu8l\" data-styles-preset=\"joHcNFWNL\" dir=\"auto\"\u003eAll products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch2 class=\"framer-text framer-styles-preset-17n1ut5\" data-styles-preset=\"Ze7_hb2TJ\" dir=\"auto\"\u003e\n\u003cbr\u003eIGF-1 LR3 Overview\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-8mbkxy\" data-framer-name=\"Overview Body\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003eIGF-1 LR3 is an 83-amino acid synthetic polypeptide engineered to overcome limitations of native IGF-1 through two strategic modifications: glutamic acid-to-arginine substitution at position 3 and addition of a 13-residue N-terminal extension (MFPAMPLSSLFVN). These alterations reduce binding affinity for IGFBPs by approximately 100-fold while maintaining full target receptor activation capacity, resulting in increased bioavailability and extended half-life compared to native IGF-1. Research models examine its activation of tyrosine kinase signaling, downstream PI3K-Akt and Ras-MAPK pathways, effects on substrate uptake in experimental models, protein synthesis stimulation, and molecular proliferation in laboratory settings.\u003cbr class=\"framer-text\"\u003e\u003cbr class=\"framer-text\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1377548\/\" rel=\"noopener\" target=\"_blank\"\u003eFrancis et al. (1992). \u003c\/a\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1482369\/\" rel=\"noopener\" target=\"_blank\"\u003eCastellino et al. (1992).\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-1ofh0jr hidden-ealwq8 hidden-4mqil7\" data-framer-name=\"History\"\u003e\n\u003cdiv class=\"framer-7d5d5p\" data-framer-name=\"History Header\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003ch2 class=\"framer-text framer-styles-preset-17n1ut5\" data-styles-preset=\"Ze7_hb2TJ\" dir=\"auto\"\u003eHistory\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-1e0s2rr\" data-framer-name=\"History Body\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003eIGF-1 LR3 was developed in the early 1990s by researchers seeking to create a more stable and bioavailable form of IGF-1 for experimental applications. The modifications were first characterized by Francis, Ross, and colleagues at GroPep Bioreagents, who demonstrated that the arginine substitution and N-terminal extension dramatically reduced IGFBP binding while preserving IGF-1 receptor affinity. This engineered analog enabled more consistent experimental outcomes by circumventing the regulatory constraints imposed by binding proteins in biological systems.\u003cbr class=\"framer-text\"\u003e\u003cbr class=\"framer-text\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1377548\/\" rel=\"noopener\" target=\"_blank\"\u003eFrancis et al. (1992).\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-1bb7rgf\" data-framer-name=\"Research Findings\"\u003e\n\u003cdiv class=\"framer-138hud5\" data-framer-name=\"Resarch Findings Header\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003ch2 class=\"framer-text framer-styles-preset-17n1ut5\" data-styles-preset=\"Ze7_hb2TJ\" dir=\"auto\"\u003eResearch Findings\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-1pwxkmo\" data-framer-name=\"Research Findings Body\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003eIGF-1 LR3 has been extensively studied in molecular signaling and pathway research, with investigations focusing on receptor-mediated signaling cascades, anabolic dynamics, substrate utilization, and molecular remodeling in various experimental models. Studies examine both its enhanced pharmacokinetic properties and downstream molecular responses.\u003c\/p\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\u003cstrong class=\"framer-text\"\u003eKey Areas of Research:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul dir=\"auto\" class=\"framer-text\"\u003e\n\u003cli data-preset-tag=\"p\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\n\u003cp class=\"framer-text framer-styles-preset-2if8ww\"\u003eSignaling: PI3K-Akt, MAPK-ERK, tyrosine kinase\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-preset-tag=\"p\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\n\u003cp class=\"framer-text framer-styles-preset-2if8ww\"\u003eSubstrate: Uptake dynamics, lipid pathways, amino acid\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-preset-tag=\"p\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\n\u003cp class=\"framer-text framer-styles-preset-2if8ww\"\u003eAnabolic: Protein synthesis, proliferation, nitrogen\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-preset-tag=\"p\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\n\u003cp class=\"framer-text framer-styles-preset-2if8ww\"\u003eMolecular: Differentiation, survival signaling, viability\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003eTogether, these investigations demonstrate IGF-1 LR3's potent activation of signaling pathways. As a modified IGF-1 analog with reduced IGFBP binding, LR3 provides a research framework for examining target receptor biology, anabolic signaling mechanisms, and downstream pathway characterization in diverse experimental systems.\u003c\/p\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1377548\/\" rel=\"noopener\" target=\"_blank\"\u003eFrancis et al., Journal of Molecular Endocrinology, 1992\u003c\/a\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1482369\/\" rel=\"noopener\" target=\"_blank\"\u003eCastellino et al., Biochemical and Biophysical Research Communications, 1992\u003c\/a\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-2if8ww\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.ni%20h.gov\/19426813\/\" rel=\"noopener\" target=\"_blank\"\u003eLu et al., Protein Expression and Purication, 2009\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-14l2n57\" data-border=\"true\" data-framer-name=\"References\"\u003e\n\u003cdiv class=\"framer-15p1962\" data-framer-name=\"Content\"\u003e\n\u003cdiv class=\"framer-1ecatqh\" data-framer-name=\"Research Use Only\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003ch2 class=\"framer-text framer-styles-preset-17n1ut5\" data-styles-preset=\"Ze7_hb2TJ\" dir=\"auto\"\u003eReferences\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"framer-1383kxn\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv class=\"framer-8qnss1\" data-framer-name=\"Research Use Only\" data-framer-component-type=\"RichTextContainer\"\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-pl80se\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1377548\/\" rel=\"noopener\" target=\"_blank\"\u003eFrancis G.L. et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3):213-223.\u003c\/a\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-pl80se\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1482369\/\" rel=\"noopener\" target=\"_blank\"\u003eCastellino F.J. et al. (1992). Receptor binding and mitogenic potency of insulin-like growth factor I analogues modied at position 3. Biochemical and Biophysical Research Communications, 189(3):1641-1648.\u003c\/a\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\" class=\"framer-text framer-styles-preset-pl80se\"\u003e\u003ca class=\"framer-text framer-styles-preset-dxoa8s\" href=\"https:\/\/pubmed.ncbi.nlm.ni%20h.gov\/19426813\/\" rel=\"noopener\" target=\"_blank\"\u003eLu Z. et al. (2009). Expression and purification of recombinant human long-R3 insulin-like growth factor-I in Pichia pastoris. Protein Expression and Purification, 67(1):38-43.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Peptiders","offers":[{"title":"1mg \/ Single Vial","offer_id":44973178650710,"sku":null,"price":79.0,"currency_code":"USD","in_stock":true},{"title":"1mg \/ Pack of 10","offer_id":44973178683478,"sku":null,"price":699.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/8787\/7206\/files\/IGF-1LR3.avif?v=1781650333","url":"https:\/\/peptidersresearch.com\/products\/igf-1-lr3","provider":"Peptiders Researcher","version":"1.0","type":"link"}